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Abstract We have clinically isolated a methicillin-resistant
Staphylococcus aureus (MRSA) K-1 which exhibits enhanced
arbekacin (Abk) resistance. In this study, we investigated a
molecular mechanism for the overproduction of a bifunctional
enzyme catalyzing both 2Q-O-phosphorylation and 6P-N-acetyla-
tion of aminoglycoside antibiotics that is encoded by aacA-aphD
and designated [AAC(6P)/APH(2Q)] and is expressed in MRSA
K-1. The sequence analysis of the 5P-adjacent region of the
aacA-aphD structural gene in MRSA K-1 showed that 12 bp
are deleted from the aacA-aphD promoter region when com-
pared with that in MRSA B-26, which exhibits lower resistance
to Abk than K-1. By arti¢cially deleting the 12 bp from the
corresponding region in MRSA B-26, we con¢rmed that the
strain increases Abk resistance to the same level as seen in
MRSA K-1, which suggests that the 12 bp deletion from the
5P-adjacent region of the aacA-aphD structural gene created a
strong promoter to overexpress the bifunctional enzyme.
4 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Because of the clinical use of methicillin and related anti-
biotics such as cephems of the third generation, methicillin-
resistant Staphylococcus aureus (MRSA) has appeared and
di¡used throughout the world. MRSA expresses resistance
to the antibiotic by producing a speci¢c penicillin-binding
protein, designated PBP2P [1]. The protein, encoded by
mecA [2], has a decreased binding a⁄nity for methicillin [1].
The appearance of MRSA has given rise to a serious problem,
namely, that MRSA exhibits drug resistance to many kinds of
antibiotics in addition to methicillin. We have in fact found
that almost all strains of MRSA isolated at Hiroshima Uni-
versity Hospital, Japan, were resistant even to an anti-tumor
agent, bleomycin (Bm), which had not been used as an anti-
bacterial agent [3^5].
Vancomycin, a glycopeptide antibiotic, has been used to
treat MRSA infections worldwide. In Japan, arbekacin
(Abk), a semi-synthetic aminoglycoside antibiotic that exhibits
lower side e¡ects than vancomycin, has also been used. Abk
has both amino and hydroxyl groups, which can be modi¢ed
by several aminoglycoside antibiotic-inactivating enzymes.
However, Abk expresses anti-bacterial activity to a wide vari-
ety of aminoglycoside antibiotic-resistant bacteria [6]. This is
because a 4-amino-2-hydroxybutyric acid group contained in
the Abk molecule plays a key role to protect the antibiotic
from inactivation by a variety of aminoglycoside antibiotic-
modifying enzymes [6].
Methicillin-sensitive S. aureus (MSSA) FDA209P, a stan-
dard strain for the measurement of drug resistance, is very
sensitive to Abk, which for this strain exhibits a minimum
inhibitory concentration (MIC) below 0.2 Wg/ml. MRSA
B-26 is a Bm-resistant strain isolated at Hiroshima University
Hospital [3^5]. MRSA B-26 was less susceptible to Abk
(MIC=1.56 Wg/ml) than FDA209P, an e¡ect mediated by a
bifunctional enzyme [AAC(6P)/APH(2Q)] that catalyzes both
2Q-O-phosphorylation and 6P-N-acetylation [7]. We have re-
cently found that a strain isolated from a patient infected
with MRSA exhibited a higher resistance to Abk than B-26.
The MIC to Abk in the strain, designated MRSA K-1, is 12.5
Wg/ml. The objective of this study was to elucidate the reason
that MRSA strain K-1 exhibits enhanced Abk resistance.
2. Materials and methods
2.1. Bacterial strains and plasmids used
MSSA FDA209P was used as a S. aureus strain that is very suscep-
tible to Abk. Ten MRSAs, which were clinically isolated at hospitals
in Hiroshima during 1991^1996, are coagulase type VII strains.
MRSA B-26 [3^5], a coagulase type II strain isolated as a Bm-resis-
tant strain at the Hiroshima University Hospital, is more resistant
(MIC=1.56 Wg/ml) to Abk than FDA209P. MRSA K-1, which was
clinically isolated recently at the Hiroshima Prefectural Hospital, is
more resistant to Abk (MIC=12.5 Wg/ml) than the B-26 strain. The
bacterium, which is a coagulase type II strain, is also resistant to Bm.
Escherichia coli JM109 and pUC18, pUC19, and pUC119 were used
as a host and vectors for cloning experiments, respectively. E. coli
XL1-Blue was used as a host for the assay of chloramphenicol acetyl-
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transferase (CAT) gene expression. S. aureus RN4220 [8] was used as
a host strain to introduce aacA-aphD.
2.2. Determination of the MIC
The MIC of Abk to MRSA was determined according to the meth-
ods established by the Japanese Society of Chemotherapy [9].
2.3. Assay of aminoglycoside antibiotic acetyltransferase (AAC) and
aminoglycoside antibiotic phosphotransferase (APH) activities
Bacterial cells, grown in LB medium at 37‡C for 12 h, were col-
lected by low-speed centrifugation, washed using an AAC assay bu¡er
(10 mM Tris^HCl pH 7.4, 10 mM magnesium acetate, 10 mM am-
monium chloride, and 1 mM 2-mercaptoethanol) or an APH assay
bu¡er (20 mM Tris^HCl pH 7.4, 10 mM magnesium acetate, 2.5 mM
ammonium chloride, 1 mM KCl, and 0.2 mM dithiothreitol (DTT))
and suspended in the same bu¡er. To obtain the cell-free extract, the
S. aureus cells were incubated for 1 h at 37‡C together with 20 Wg
lysostaphin before sonication, but the E. coli cells were sonicated
without prior treatment. The cell-free extract was centrifuged at
16 000Ug for 10 min at 4‡C, and the resulting supernatant was
used as an enzyme solution. AAC or APH activity was analyzed as
described previously by the phosphocellulose paper-binding assay
method [10]. One unit of AAC or APH activity was de¢ned as the
amount of enzyme that catalyzes conversion of 1 Wmol of aminoglyco-
side antibiotic in 1 min.
2.4. Southern blotting
S. aureus cells grown in LB medium for 12 h at 37‡C were washed
with solution I (25 mM Tris^HCl pH 8.0, 50 mM glucose, and 25 mM
EDTA) and suspended in the same solution. After the cells had been
lysed by lysostaphin supplemented with 10% sodium dodecyl sulfate
(SDS), the chromosomal DNA was isolated. Southern blot hybridiza-
tion was principally performed according to the general method [11].
The chromosomal DNA was digested with the given restriction en-
zymes (XbaI, PstI, and HindIII), electrophoresed in agarose gel, and
followed by blotting onto a nylon membrane (Hybond N+, Amer-
sham, Sweden). DNA hybridization was done at 55‡C overnight in a
5USSPE, 0.5% SDS, 5UDenhard’t solution, and 20 Wg/ml sheared
calf thymus DNA supplemented with the DNA probe labeled with [K-
32P]dATP using the Nick Translation Kit (Takara Shuzo, Japan). The
probe was part of the aacA-aphD gene (+212^+900; A in the ATG
start codon of aacA-aphD=+1) [12], obtained by polymerase chain
reaction (PCR), with primers 5P-GTTCCTATTGGATATGGA-
CAAATAT-3P and 5P-TCGTTTTAACAAATTTTGTTCTTCT-3P us-
ing chromosomal DNA from MRSA B-26 as a template. After hy-
bridization, the nylon membrane was washed twice with 2USSPE
containing 0.1% SDS at 55‡C for 10 min and then rinsed with
1USSPE containing 0.1% SDS for 15 min at the same temperature.
2.5. Northern blotting
S. aureus cells grown until 1 OD600nm in LB medium were sus-
pended in STET bu¡er (10 mM Tris^HCl pH 8.0, 8% sucrose, 0.5%
Triton X-100, and 50 mM EDTA) and lysostaphin added to 100 Wg/
ml for cell lysis. Total RNA from the cell lysate was isolated using
Isogen (Nippon Gene, Japan) based on the method of Chomczynski
and Sacchi [13]. The RNA (40 Wg) was electrophoresed in formalde-
hyde containing agarose gel and blotted onto a nylon membrane
(Hybond N+) [11]. After pre-hybridization of RNA had been carried
out at 45‡C for 1^2 h, the 32P-labeled DNA was hybridized to RNA
on the membrane at 45‡C for 12 h. The probe DNA was the same as
that used for Southern blotting analysis.
2.6. DNA sequencing
The staphylococcal DNA fragment, subcloned into pUC119, was
used for the construction of deletion mutants with a Kilo-Sequence
Deletion Kit (Takara Shuzo, Japan). DNA was sequenced by the
dideoxy chain termination method [14] using an AutoRead Sequenc-
ing Kit and the A.L.F. DNA sequencer (Pharmacia LKB Biotechnol-
ogy, Sweden). The sequence data were analyzed for an open reading
frame and for a promoter region with GENETYX (Software Devel-
opment, Japan).
2.7. Determination of the transcriptional starting point by the primer
extension method
An annealing reaction mixture consisting of RNA (10 or 30 Wg) and
a biotin-labeled primer (1.5 pmol) were incubated at 65‡C for 10 min
and then cooled to 37‡C. A 20 Wl portion of the annealing sample was
mixed with 10 Wl of a 5U¢rst-strand bu¡er, 5 Wl of 0.1 M DTT, 2.5 Wl
of 10 mM dNTP, 5 Wl of actinomycin D (1 mg/ml), and 7.5 Wl of
water and incubated at 42‡C for 2 min before the addition of reverse
transcriptase (Superscript II, Gibco, USA). After the primer extension
experiment had been done at 42‡C for 20 min, the reaction was
stopped by incubation at 37‡C for 20 min after the addition of 10
Wl RNase A (2 mg/ml). The resulting DNA was treated with phenol/
chloroform and puri¢ed by ethanol precipitation. The puri¢ed DNA
was denatured and applied to a 6% acrylamide gel containing 7 M
urea. After electrophoresis at 35 W for 2^6 h, the DNA was trans-
blotted onto a nylon membrane (Biodyne B, Japan Genetics, Japan).
Detection of DNA was carried out using a Phototope-Star Detection
Kit (New England Biolabs, UK) according to the supplier’s instruc-
tion manual. Primer A (5P-TATACATATTTCATTTTCAACTA-
TATTCAT-3P), which anneals to the 5P-adjacent region of the
aacA-aphD structural gene, and primer B (5P-AAAAGTGTATAG-
CAATATGCAAATCCTATA-3P), which hybridizes to the nucleotide
sequence located 270 bases upstream of the aacA-aphD structural
gene, were used in the primer extension.
2.8. Assay of the MRSA’s promoter activity in E. coli
To amplify the aacA-aphD structural gene together with Palr or
Pahr in K-1 and B-26 by PCR, three kinds of sense primers, P1B
(5P-TCAAGGATCCACATCAATTTTGATAAGTAG-3P), P2B (5P-
TATAGGATCCTACACAGGAGTCTGGACTTG-3P), and P3B (5P-
ATATGGATCCTGATATTGATAATTTAAAAG-3P), and an anti-
sense primer, PEE (5P-CACTTGAATTCTTATTTTTCATTTTTT-
TAA-3P), were synthesized. Each aacA-aphD, including Palr or
Pahr, was ampli¢ed using the chromosomal DNA from K-1 and
B-26 with the antisense primer and each sense primer in turn. The
resulting ampli¢ed DNA was cloned into pUC18 to generate p18D1B-
26, p18D2B-26, p18D1K-1, p18D2K-1, and p18D3K-1 (see Fig. 4A).
E. coli JM109, transformed with one of these plasmids, was analyzed
for the [AAC(6P)/APH(2Q)] activity.
Promoter activities were also evaluated using a CAT assay. Using
the sense primers P1B and P2B, and the antisense primers P1PH (5P-
ATTAAAGCTTCTTCCATAAACTCAGTCAAG-3P) and P2PH (5P-
TATCATTAAGCTTTCCTTTTAAATTATCAA-3P), the Palr or
Pahr promoter from the K-1 and B-26 strains was ampli¢ed by
PCR. Each PCR-ampli¢ed promoter was inserted into the CAT assay
vector, pKK232-8 [15], to generate p1CATB-26, p2CATB-26,
p1CATK-1, and p2CATK-1 (see Fig. 4B). The CAT activity in
E. coli XL1-Blue harboring one of these plasmids was analyzed as
follows: a 4 Wl portion of seed culture grown at 37‡C overnight was
inoculated into 4 ml of an LB medium and cultivated until 0.5
OD600nm. The culture was induced with 0.3 mM IPTG and grown
for 4 h. The cells collected by centrifugation at 1800Ug for 5 min
were washed with 0.25 M Tris^HCl (pH 7.6), suspended into the same
bu¡er, and sonicated for 10 min. The supernatant obtained by cen-
trifugation was used as an enzyme solution for the CAT assay, which
was performed as described elsewhere [11]. One unit of CAT activity
was de¢ned as the amount of enzyme that acetylated 1 nmol of the
chloramphenicol in 1 min.
2.9. Induction of plasmid DNA into the S. aureus cells
Competent S. aureus were prepared according to the method of
Schenk and Laddaga [16]. A 70 Wl portion of the cell suspension
was mixed with 5 Wl of DNA solution (6 1 Wg) and transferred into
a 1 cm gap cuvette. Electroporation was done with an Electroporator
II (Invitrogen, USA) with 70 6, 50 WF, and 1.7 kV. After the addition
of 390 Wl of a B2 medium [16], the cell suspension was kept for 1^4 h
at 28^37‡C and spread on a plate containing LB medium supple-
mented with the given antibiotic.
2.10. Homologous recombination experiment of the S. aureus
chromosome
A 2.5 kb HindIII-HindIII fragment containing aacA-aphD, which
was excised from p19AMEK, was subcloned into pTS-1 [17] to gen-
erate pTSAGK. The chimeric plasmid was introduced into S. aureus
RN4220 by electroporation described above. The plasmid, pTSAGK,
puri¢ed from the transformant, was used for homologous recombina-
tion into MRSA B-26 according to the methods described previously
[18,19]. This yielded MRSA B-26, in which the promoter of the aacA-
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aphD gene was replaced by that of the K-1 strain. The accuracy of the
recombination was con¢rmed by sequencing of the aacA-aphD gene
and Southern blot analysis.
3. Results and discussion
3.1. Abk resistance of MRSA isolated clinically at a hospital in
Japan
Eleven MRSA strains including B-26, which were clinically
isolated at hospitals in Hiroshima, Japan, from 1991 to 1996,
were randomly selected. They exhibited MICs from 0.78 to
3.13 Wg/ml of Abk, compared to 0.2 Wg/ml for the MSSA
FDA209P. Interestingly, the MIC of Abk for MRSA K-1,
which was recently isolated at the Hiroshima Prefectural Hos-
pital, increased to 12.5 Wg/ml (Table 1). All of these MRSAs
were highly resistant to dibekacin (Dbk) and gentamicin (Gm)
over 100 Wg/ml.
3.2. Relationship between Abk resistance and
[AAC(6P)/APH(2Q)]
We determined the [AAC(6P)/APH(2Q)] activity in cell-free
extracts from the above 11 MRSAs and K-1 strains. Dbk, an
antibiotic lacking a 4-amino-2-hydroxybutyryl group con-
tained in the Abk molecule, was also used as a substrate to
assay the [AAC(6P)/APH(2Q)] activity. As listed in Table 1,
enzyme activity was observed in MRSA K-1 and in 11
MRSAs from hospitals in Hiroshima; however, none was
observed in S. aureus FDA209P. The [AAC(6P)/APH(2Q)] ac-
tivity in MRSA K-1 was much higher than that in other
MRSA strains, suggesting that the enhanced Abk resistance
in MRSA K-1 may depend on the overexpression of
[AAC(6P)/APH(2Q)].
3.3. Northern blot analysis of the aacA-aphD gene transcript in
MRSA
The above observation led us to investigate the reason for
the overproduction of [AAC(6P)/APH(2Q)] in MRSA K-1. We
analyzed the transcript of aacA-aphD using the probe de-
scribed in Section 2.4. Northern blot analysis revealed a 2.5
kb transcript in both MRSA K-1 and B-26 strains but not in
S. aureus FDA209P (Fig. 1A). The amount of K-1 transcript
was higher than in strain B-26, suggesting that the overpro-
duction of [AAC(6P)/APH(2Q)] in the K-1 strain may be due to
the increased transcription of aacA-aphD.
3.4. Copy number of aacA-aphD in MRSA K-1
The transposon Tn4001 consists of an aacA-aphD gene, a
cryptic gene, orf132, and two IS256s, between which aacA-
aphD and orf132 are located. Tn4001 is integrated into a
plasmid or chromosome of S. aureus by mediation of a trans-
posase in IS256 [20]. There is a possibility that an increment
of the copy number of Tn4001, integrated into the K-1 chro-
mosome, may give rise to overexpression of the aacA-aphD
transcript. Therefore, we performed Southern blot analysis of
the chromosomal DNAs from K-1 and B-26 strains using the
shortened aacA-aphD probe. Genomic Southern analyses in
MRSA K-1 and B-26 strains showed only single bands hy-
bridizing to the probe (Fig. 1B). These observations suggest
that there is one copy of the aacA-aphD gene per chromosome
Table 1
MIC (Abk) and [AAC(6P)/APH(2Q)] activities in clinically isolated
MRSAs
strains [AAC(6P)/APH(2Q)] speci¢c activity
(U/mg protein)
MIC (Wg/ml)
AAC APH
Abk Dbk Abk Dbk
B-26 1.22 6.50 1.61 7.98 1.56
K-1 5.04 24.3 6.58 33.2 12.5
K-2 1.20 5.53 1.58 7.58 3.13
K-3 1.24 6.96 1.64 8.46 1.56
K-4 1.20 6.57 1.48 8.06 1.56
K-5 1.03 5.31 1.40 7.31 0.78
D-1 1.09 5.40 1.42 6.78 1.56
D-2 1.33 7.22 1.69 8.78 3.13
D-3 0.73 3.97 1.26 5.43 0.78
D-4 1.56 8.71 1.90 9.90 3.13
S-1 1.35 6.83 1.85 8.22 1.56
S-2 0.68 3.25 0.90 4.63 0.78
Fig. 1. A: Northern blot analysis of the transcription of the aacA-aphD gene. Total RNA (40 Wg) isolated from FDA209P, K-1, and B-26
strains was analyzed using an incomplete aacA-aphD fragment as a probe. The rRNA positions (16S and 23S) are indicated on the left side of
the panel. Lanes: 1, FDA209P; 2, K-1; 3, B-26. B: Analysis of the copy number of the aacA-aphD gene in MRSAs B-26 and K-1. The chro-
mosomal DNAs from the B-26 and K-1 strains, digested with the given restriction enzyme, were analyzed by the Southern blotting technique
using the same aacA-aphD probe as used in A. Molecular sizes are indicated on the left side of the panel. Lanes: 1, XbaI-digested B-26;
2, XbaI-digested K-1; 3, PstI-digested B-26; 4, PstI-digested K-1; 5, HindIII-digested B-26; 6, HindIII-digested K-1.
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and that the increased transcription of aacA-aphD in K-1 is
not due to an increase of the Tn4001 copy number. Interest-
ingly, the XbaI-digested hybridizing DNA bands in K-1 and
B-26 have sizes of 4.9 and 7.6 kb, respectively (Fig. 1B), sug-
gesting that the integration site of Tn4001 into the K-1 chro-
mosome may di¡er from that into the B-26 chromosome. We
found that MRSA K-1 possesses a plasmid of 5.5 kb but that
aacA-aphD is absent in the plasmid (data not shown).
3.5. Cloning of aacA-aphD from K-1 and B-26 strains and
determination of their nucleotide sequences
To clarify the reason for the overexpression of aacA-aphD
in K-1, we cloned a 2.5 kb HindIII-HindIII fragment carrying
orf132, aacA-aphD, and a part of IS256 from the chromosom-
al DNA of K-1 and B-26, respectively. The DNA fragments
from B-26 and K-1 were inserted into pUC19 to generate
p19AMEB and p19AMEK, respectively. Although each 2.5
kb DNA fragment from both strains was inserted into
pUC19 in an orientation opposite that of the lac promoter,
the transformed E. coli cells exhibited high resistance to Dbk
(MICs 100 Wg/ml), Gm (MICs 100 Wg/ml), and kanamycin
(MICs 100 Wg/ml). This suggests that in both cases the ex-
pression of aacA-aphD is under the control of its endogenous
promoter(s). E. coli JM109 [p19AMEK] produced [AAC(6P)/
APH(2Q)] at a six-fold higher rate than E. coli JM109
[p19AMEB]. To elucidate the reasons for the increase in en-
zyme activity, we determined the nucleotide sequence of these
two 2.5 kb HindIII-HindIII DNA fragments. We found that
although orf132 and aacA-aphD are exactly the same in both
strains, 12 bp in the 5P-adjacent region of the aacA-aphD
structural gene in K-1 were deleted when compared with
B-26 (Fig. 2). The corresponding regions from all MRSA
strains, which exhibit MICs from 0.78 to 3.13 Wg/ml to
Abk, were exactly the same as in MRSA B-26.
Fig. 2. Nucleotide sequences of the 5P-proximal region of the aacA-aphD gene in MRSAs B-26 and K-1. The 12 bp deletion in the K-1 strain
is indicated by broken lines. The putative ribosome-binding sites (RBS) for the orf132 and aacA-aphD are indicated by a thick line. The start
codons (ATG) for orf132 and aacA-aphD are indicated by bold type. A putative promoter for the aacA-aphD gene in MRSA B-26 is designated
as Palr. Palr is also present in the K-1 strain. A putative promoter, Pahr, newly generated by the 12 bp deletion, is present in K-1. Deduced
335 and 310 regions for each promoter are indicated by a box. The transcriptional start points are indicated by italicized bold type. The nu-
cleotide number is based on the literature [12].
Fig. 3. Transcriptional start points of the aacA-aphD gene in MRSAs B-26 (A) and K-1 (B). The transcriptional start point of aacA-aphD in
B-26 was determined to be guanine or thymine, located approximately 420 bp upstream of the aacA-aphD initiation codon by primer extension
analysis using primer B. In K-1 the transcriptional start was at a guanine located approximately 360 bp upstream of the aacA-aphD initiation
codon. The asterisk indicates the transcriptional start point.
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3.6. Transcriptional starting point of aacA-aphD in K-1 and
B-26 strains
We determined and compared the transcriptional starting
point of aacA-aphD between MRSAs K-1 and B-26 by the
primer extension method. When using primer A, the resulting
reverse transcripts from the K-1 and B-26 RNAs had sizes of
approximately 350 and 400 bases, respectively (data not
shown). Signi¢cantly, the amount of DNA product from
K-1 was greater than that from B-26, although the amount
of RNA used for B-26 was three-fold higher than that used
for K-1. In addition to the 350 base DNA band, four DNA
bands were also observed in the K-1 strain. Two of the four
bands had the same size as those observed in the B-26 strain.
However, these four bands were very faint. These results sug-
gest that, although the aacA-aphD of the K-1 strain is weakly
transcribed from the same promoter as that of B-26, over-
transcription of aacA-aphD might be due to the fact that
the promoter is di¡erent from that of the B-26 strain. Since
clari¢cation of the transcriptional starting point using primer
A was di⁄cult, it was replaced by primer B. The transcrip-
tional starting point of aacA-aphD in K-1, determined by us-
ing 10 Wg RNA, was guanine, located about 360 bp upstream
of the initiation codon (Figs. 2 and 3B), but that in B-26 was
guanine or thymine, located about 420 bp upstream of it
(Figs. 2 and 3A). When determined with 30 Wg RNA, addi-
tional transcriptional starting points, which are the same as
those of B-26, were also observed in the K-1 strain (data not
shown).
3.7. The putative promoter sequence of aacA-aphD in K-1
The consensus promoter sequences in the E. coli gene are
TTGACA (335 region) and TATAAT (310 region). Through
sequence analysis with the program GENETYX we presumed
that the corresponding sequences are TAGAAA and TAG-
CAT in the B-26 aacA-aphD (Fig. 2). The promoter, desig-
nated Palr, was also present in K-1. We found an additional
promoter sequence (TTGACT and TAATAT) located down-
stream of the K-1 Palr, which was generated by deletion of 12
bp (Fig. 2). The promoter, designated Pahr, is highly similar
to the E. coli consensus sequence.
3.8. Comparison of the promoter activity of Palr and Pahr
The promoter activity of the original promoter Palr and the
newly generated putative promoter Pahr was compared in this
study. Each aacA-aphD, including Palr or Pahr from K-1 and
B-26, was ampli¢ed by PCR. Each ampli¢ed DNA was cloned
into pUC18 to generate p18D1B-26, p18D2B-26, p18D1K-1,
p18D2K-1, and p18D3K-1 (Fig. 4A). For each plasmid trans-
formed into E. coli JM109 we determined the MIC of Abk
and Dbk and assayed the [AAC(6P)/APH(2Q)] activity (Table
2). E. coli [p18D1B-26] produced signi¢cant amounts of bi-
functional enzyme, whereas the same host transformed with
p18D2B-26 scarcely produced the enzyme due to deletion of
Palr. E. coli [p18D1K-1] produced the enzyme at a six-fold
higher level than the same host carrying p18D1B-26, indicat-
ing that the enzyme productivity at the higher level is depen-
dent on Pahr. In addition, although E. coli transformed with
p18D2B-26 did not express the [AAC(6P)/APH(2Q)] activity,
E. coli [p18D2K-1] harboring Pahr produced the same
amount of enzyme as E. coli [p18D1K-1]. These results indi-
cate that Palr and Pahr function in E. coli cells and that the
promoter activity of Pahr is signi¢cantly higher than that of
Palr.
Promoter activities were also evaluated by a CAT assay.
The Palr or Pahr promoter from K-1 and B-26 strains was
ampli¢ed by PCR. Each PCR-ampli¢ed promoter was in-
serted into the CAT assay vector to generate p1CATB-26,
p2CATB-26, p1CATK-1, and p2CATK-1 (Fig. 4B). The
CAT activity in E. coli XL1-Blue harboring one of these
plasmids was analyzed. The activity in E. coli [p1CATK-1]
was about nine-fold higher than that in E. coli [p1CATB-
Fig. 4. A: Representation of plasmids used to evaluate the promoter
activity of Palr and Pahr. DNA fragments containing Palr and/or
Pahr together with orf132 and aacA-aphD were ampli¢ed by PCR
from MRSAs B-26 and K-1, and subcloned into pUC18 to generate
the plasmids shown. E. coli JM109 harboring each plasmid was ana-
lyzed for [AAC(6P)/APH(2Q)] activity. The position of primers (P1B,
P2B, P3B, and PEE), used to amplify each fragment, is indicated by
a small arrow. B: Promoter activity of Palr and Pahr. DNA frag-
ments containing Palr from B-26 and those containing Pahr, or Palr
and Pahr, from K-1 were ampli¢ed by PCR. Each fragment was in-
serted into a CAT assay vector, pKK232-8 [15], to generate the
plasmids shown. The CAT activity in E. coli XL1-Blue harboring
each plasmid was analyzed to evaluate the promoter activity. The
position of primers (P1B, P2B, P1PH, and P2PH), used to amplify
each fragment, is indicated by a small arrow.
Table 2
MIC (Abk and Dbk) and [AAC(6P)/APH(2Q)] activity in E. coli JM109 harboring p18D1B-26, p18D2B-26, p18D1K-1, p18D2K-1 or p18D3K-1
Strain MIC (Wg/ml) [AAC(6P)/APH(2Q)] speci¢c activity (U/mg protein)
Abk Dbk AAC APH
Abk Dbk Abk Dbk
JM109 [p18D1B-26] 0.78 3.13 0.0076 0.035 0.0081 0.039
JM109 [p18D2B-26] 0.39 1.56 0.0021 0.010 0.0026 0.012
JM109 [p18D1K-1] 1.56 25 0.046 0.221 0.046 0.228
JM109 [p18D2K-1] 1.56 50 0.040 0.210 0.042 0.219
JM109 [p18D3K-1] 0.39 1.56 0.0024 0.012 0.0027 0.013
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26], again suggesting that Pahr is involved in the high activity.
E. coli [p2CATK-1] exhibited about eight-fold higher activity
than that harboring p2CATB-26, showing that Pahr expresses
stronger transcriptional activity than Palr when introduced
into E. coli.
3.9. E¡ect of 12 bp deletion in the promoter region of
aacA-aphD in the B-26 strain
The CAT assay showed that Pahr expresses stronger tran-
scriptional activity than Palr in E. coli. It is likely that Pahr
shows stronger activity than Palr in S. aureus, thus explaining
why the K-1 strain overexpresses the aacA-aphD gene. How-
ever, Southern blot analysis indicated that the integration site
of Tn4001 into chromosomal DNA is di¡erent between B-26
and K-1 strains (Fig. 1B). The di¡erent integration may a¡ect
the aacA-aphD transcription. To distinguish between these
possibilities, we introduced a 12 bp deletion into the promoter
region of the aacA-aphD gene in B-26 by the homologous
recombination method [18,19]. The deletion was con¢rmed
by sequencing the promoter region of the aacA-aphD gene
from the resulting disruptant, designated MRSA B-26K.
Southern blot analysis of the XbaI-digested B-26K chromo-
some con¢rmed that the position of aacA-aphD integrated
into the B-26K chromosome was the same as in the original
B-26 strain (data not shown). The resistance to Abk
(MIC=12.5 Wg/ml) in MRSA B-26K was the same as in
MRSA K-1. In addition, the [AAC(6P)/APH(2Q)] activity in
B-26K was almost the same as that in K-1. These results
show that the 12 bp deletion from the aacA-aphD promoter
region converts the B-26 stain to a K-1-like strain (B-26K),
regardless of the di¡erence of the integration position of
aacA-aphD into the chromosome.
In conclusion, MRSA K-1, which exhibits enhanced Abk
resistance, can produce a large amount of [AAC(6P)/APH(2Q)]
enzyme as a result of the increased transcription of aacA-
aphD. The present study shows that the transcriptional over-
expression is dependent on a strong promoter, newly gener-
ated by a 12 bp deletion in the aacA-aphD promoter region.
Recently, two MRSA strains with high Abk resistance
(MIC=64 Wg/ml) have been reported [21]. One strain produ-
ces [AAC(6P)/APH(2Q)] together with AAD(4P,4Q), and the
other expresses [AAC(6P)/APH(2Q)] together with APH(3P)-
III. It will be of interest to investigate the molecular mecha-
nism underlying the high Abk resistance in these MRSAs.
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